N
WHWK

Nuveen’s Whitehawk Therapeutics WHWK Stock Holding History

Nuveen’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-20,913
Closed -$48.9K – 3434
2024
Q1 		$48.9K Hold
20,913
– – ﹤0.01% 3269
2023
Q4 		$42.2K Hold
20,913
– – ﹤0.01% 3307
2023
Q3 		$101K Hold
20,913
– – ﹤0.01% 3121
2023
Q2 		$143K Hold
20,913
– – ﹤0.01% 3136
2023
Q1 		$151K Hold
20,913
– – ﹤0.01% 3022
2022
Q4 		$268K Hold
20,913
– – ﹤0.01% 3008
2022
Q3 		$296K Hold
20,913
– – ﹤0.01% 3049
2022
Q2 		$258K Buy
+20,913
New +$311K ﹤0.01% 3121

Other funds holding WHWK

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Acuitas Investments Seattle, Washington $1.41M AUM 48.57% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Nuveen's WHWK Position: Q2 2024 in Review

Nuveen sold out of Whitehawk Therapeutics (WHWK) in Q2 2024, closing a stake of 20,913 shares — an estimated $48.9K sold.

Nuveen first reported a position in WHWK in Q2 2022 and held it in 8 quarters. The position peaked at $296K in Q3 2022. 65 funds tracked by Wall St. Rank hold WHWK as of Q2 2024.

  • Nuveen reported no remaining Whitehawk Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Nuveen sold 20,913 Whitehawk Therapeutics shares in Q2 2024, an estimated $48.9K.
  • Nuveen first reported a position in Whitehawk Therapeutics in Q2 2022 and held it in 8 quarters.
  • Nuveen's Whitehawk Therapeutics position peaked at $296K in Q3 2022.
  • 65 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q2 2024.

Based on Nuveen's 13F filing for Q2 2024, filed 9 Aug 2024.